Ultra-pure EPA Composition for Triglyceride Reduction Without LDL-C Elevation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cardiovascular-related diseases, particularly those involving high triglycerides and LDL-C levels, often fail to effectively lower triglycerides in patients on stable statin therapy without causing significant increases in LDL-C levels.

Innovation Solution

Administering a pharmaceutical composition comprising at least 90% ethyl eicosapentaenoate or ultra-pure EPA, ranging from 1g to 4g daily, to patients with baseline fasting triglycerides between 200 mg/dL and 500 mg/dL on stable statin therapy, which has been shown to lower triglycerides and maintain or decrease LDL-C levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Weight of moving object

If conventional statin therapy is used to lower LDL-C levels, then LDL-C levels are reduced, but triglyceride levels remain elevated or increase

Engineering Contradiction:

ImproveLDL-C levelsVSAvoidtriglyceride levels

Core Design Contradiction:

Weight of moving objectVSWeight of stationary object

Solution Approach 1:

The patent segments the lipid management problem into two distinct targets: LDL-C and triglycerides. It applies different therapeutic mechanisms to each - statins for LDL-C reduction and EPA for triglyceride reduction - allowing independent optimization of each lipid parameter without the trade-offs inherent in single-therapy approaches

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent combines statin therapy and EPA supplementation in a single treatment regimen. This merging of therapies allows simultaneous achievement of LDL-C reduction (via statins) and triglyceride reduction (via EPA), resolving the contradiction where one therapy improves one parameter while worsening another

Inventive Principle:

Principle #5Merging (Combining)

2Weight of stationary object

If triglyceride-lowering therapies are administered, then triglyceride levels decrease, but LDL-C levels increase significantly

Engineering Contradiction:

Improvetriglyceride levelsVSAvoidLDL-C levels

Core Design Contradiction:

Weight of stationary objectVSWeight of moving object

Solution Approach 1:

The patent applies preliminary anti-action by using EPA to prevent the LDL-C elevation that would normally result from triglyceride-lowering therapy. The EPA component counteracts the adverse LDL-C effect before it can fully manifest, allowing triglyceride reduction to proceed without the harmful secondary effect

Inventive Principle:

Principle #9Preliminary anti-action

3Weight of stationary object

If high doses of EPA are administered to lower triglycerides, then triglyceride reduction increases, but LDL-C levels may increase

Engineering Contradiction:

Improvetriglyceride reduction magnitudeVSAvoidLDL-C levels

Core Design Contradiction:

Weight of stationary objectVSWeight of moving object

Solution Approach 1:

The patent optimizes the EPA dosage parameter to achieve maximum triglyceride reduction while minimizing LDL-C elevation. By carefully selecting the dose range (typically 1-4 grams daily), the therapy shifts the balance toward beneficial triglyceride effects while controlling adverse LDL-C effects through parameter optimization

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS11285127B2Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Publication Date: 2022.03.29 AMARIN PHARMACEUTICALS IRELAND LIMITED(IE)

AI summary

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.